miR-125b-5p sensitizes colorectal cancer to anti-PD-L1 therapy by decreasing TNFR2 expression on tumor cells
Journal of Leukocyte Biology · 04.06.2025 · 117 (6)
DOI: 10.1093/jleuko/qiaf059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 20.05.2025. Verfasst von Yibo Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, N22-Research Building, Avenida da Universidade, …. Hauptthemen laut MEDLINE: MicroRNAs, Receptors, Tumor Necrosis Factor, Type II, Colorectal Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Macau Science and Technology Development Fund, University of Macau.
Abstract (Originalsprache)
The microRNA miR-125b-5p, recognized as a tumor suppressor, has demonstrated the ability to curb the proliferation of various types of cancer cells. Our latest research has revealed that miR-125b-5p also impedes the proliferation and functionality of CD4 + Foxp3+ regulatory T cells by reducing the expression of tumor necrosis factor receptor 2 (TNFR2) on regulatory T cells. To explore the potential of miR-125b-5p to suppress tumor growth by targeting TNFR2 on cancer cells, we overexpressed the levels of miR-125b-5p in mouse colorectal cancer cells. Our findings showed that the overexpression of miR-125b-5p significantly suppressed the proliferation, migration, and invasiveness of TNFR2-expressing cancer cells. This was further supported by in vivo observations, in which we noted a regression of 20% to 30% of tumors in immunocompetent mice that had been treated with miR-125b-5p–overexpressing cells. Remarkably, when combined with anti-PD-L1 therapy, the regression rate increased dramatically, with over 85% of mice showing a 2- to 3-fold enhancement in tumor regression. This synergistic effect was attributed to the miR-125b-5p–mediated increase in cytotoxic CD8+ T cells. In conclusion, our study suggests that miR-125b-5p, by inhibiting TNFR2 expression in colorectal cancer cells, can enhance the effectiveness of anti-PD-L1 immunotherapy. This is achieved by modulating anti-tumor immune responses. The potential of miR-125b-5p to boost the efficacy of immunotherapies in clinical settings is a promising avenue for future therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, N22-Research Building, Avenida da Universidade, University of Macau, Taipa, Macau SAR, China.
- Department of Pharmaceutical Science, Faculty of Health Sciences, Building University of Macau E12, Avenida da Universidade, University of Macau, Taipa, Macau SAR, China.
- MoE Frontiers Science Center for Precision Oncology, University of Macau, N22-Research Building, Avenida da Universidade, Taipa, Macau SAR, China.
ORCID-Profile: Chon-Kit Chou
Förderung
- Macau Science and Technology Development Fund
- University of Macau
Zitieren
APA
Chen, Y., Jiang, M., Liao, P., Yang, Y., Chen, Z., Gao, Y., Wang, Y., Chou, C. K., & Chen, X. (2025). miR-125b-5p sensitizes colorectal cancer to anti-PD-L1 therapy by decreasing TNFR2 expression on tumor cells. Journal of Leukocyte Biology, 117(6). https://doi.org/10.1093/jleuko/qiaf059
Vancouver
Chen Y, Jiang M, Liao P, Yang Y, Chen Z, Gao Y, et al. miR-125b-5p sensitizes colorectal cancer to anti-PD-L1 therapy by decreasing TNFR2 expression on tumor cells. Journal of Leukocyte Biology. 2025;117(6). doi:10.1093/jleuko/qiaf059
BibTeX
@article{Chen2025,
author = {Chen, Yibo and Jiang, Mengmeng and Liao, Ping and Yang, Yang and Chen, Zhonghao and Gao, Yang and Wang, Yiru and Chou, Chon-Kit and Chen, Xin},
title = {miR-125b-5p sensitizes colorectal cancer to anti-PD-L1 therapy by decreasing TNFR2 expression on tumor cells},
journal = {Journal of Leukocyte Biology},
year = {2025},
volume = {117},
number = {6},
doi = {10.1093/jleuko/qiaf059}
}
EUVIMED